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Introduction: Anti-arrhythmic medications (AAMs) are known to increase cardiac mortality signiﬁcantly
due to their pro-arrhythmic effects. However, the effect of AAMs on non-cardiac mortality has not been
evaluated.
Methods: Trials published in English language journals from 1990 to 2015 were thoroughly retrieved by
searching websites such as PubMed, Medline, Cochrane Library, and Google Scholar. Randomized con-
trolled trials reporting non-cardiac deaths as primary or secondary outcomes were used to compare
AAMs to non-arrhythmic therapy (AV nodal blocking agents, implantable cardiovascular deﬁbrillation
(ICD), or placebo). Information regarding the sample size, treatment type, baseline characteristics, and
outcomes was obtained by using a standardized protocol. The ﬁxed effect model was used to perform
meta-analysis, and results were expressed in terms of odds ratio (OR) with conﬁdence interval (CI) of
95%, inter study heterogeneity was assessed using I2. Intention to treat principle was applied to
extract data.
Results: Total of 18,728 patients were enrolled in 15 trials; 9359 patients received AAMs and 9369
received non-arrhythmic therapy. AAMs were associated with an increased risk of non-cardiac mortality
(OR¼1.30, [95% CI: 1.12, 1.50], p¼0.0005, I2 index¼24%) and all-cause mortality (OR¼1.09, [95% CI: 1.01,
1.18], p¼0.04, I2¼54%) as compared to non-arrhythmic therapy. There was no difference in the cardiac
mortality (OR¼1.01, [95% CI: 0.92, 1.11], p¼0.82, I2¼53%) or arrhythmic mortality (OR¼1.00, [95% CI:
0.89, 1.13], p¼0.94, I2¼64%) between the two groups.
Conclusion: AAMs are associated with an increased risk of non-cardiac and all-cause mortality. The effect
of AAMs, especially amiodarone, on non-cardiac mortality requires further evaluation.
& 2016 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Anti-arrhythmic medications (AAMs) are the most commonly
used treatment for medical management of cardiac arrhythmias
[1,2]. The use of AAMs in treatment of both atrial and ventricular
arrhythmias is limited owing to their limited efﬁcacy and long-
term toxicity. Numerous randomized trials had compared the all-
cause mortality or other arrhythmic outcomes of AAMs with either
placebo treatment or invasive interventions such as implantable
cardioverter deﬁbrillator or ablation [3–11]. Considering theblished by Elsevier B.V. This is an
pital Department of Internal
rk 10305, USA.
ndya).potential side effects of different anti-arrhythmic agents, none of
the trials had reported the effect of AAMs on non-cardiac mor-
tality. The primary aim of this meta-analysis was to analyze the
effect of anti-arrhythmic medications (AAMs) on non-cardiac
mortality.2. Methods
Two researchers identiﬁed all the published randomized trials
that had compared any AAM with non-arrhythmic therapy (AV
nodal blocking agents, implantable cardiovascular deﬁbrillation
(ICD), or placebo) and assessed the eligibility of each trial. Each
trial was required to report non-cardiac deaths as primary or
secondary outcomes.open access article under the CC BY-NC-ND license
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Two authors performed thorough literature search on Medline,
Google Scholar, and the Cochrane Library for the relevant articles
published from 1990 to April 2015. Following keywords were used
for the search: randomized, trial, antiarrhythmic, cardiac, non-
cardiac, mortality, outcomes, survival, ventricular arrhythmias,
atrial ﬁbrillation, treatment, rhythm control, amiodarone, dofeti-
lide, sotolol, propafenone, ﬂecainide, and procainamide. For a
comprehensive search abstracts from the annual meetings of the
American Heart Association, American College of Cardiology and
European Society of Cardiology were investigated for the same
time. References of all the selected journal and review articles
were reviewed so that any additional randomized trials could be
identiﬁed. The search was limited to humans and to articles
reported in English language.
Inclusion criteria for the retrieved studies were: (a) controlled
comparison of AAMs to atrial ventricular nodal blocking agents,
ICD or placebo, (b) randomized treatment allocation, (c) intention
to treat analysis, (d) reports of cardiovascular and non-
cardiovascular mortality. Studies were excluded if they had the
following criteria (a) vague treatment allocation process,
(b) signiﬁcant variability amongst study population, (c) studies
comparing two different AAMs. Standardized protocol was used to
obtain information on sample size, treatment type, medications,
baseline characteristics, and outcomes.
2.2. Outcomes
The primary outcomes of interest were total mortality, cardi-
ovascular mortality, non-cardiovascular mortality, and arrhythmic
mortality. Our research committee classiﬁed the causes of death
reported in the selected studies into cardiac mortality, arrhythmic
mortality, non-cardiac mortality, and all-cause mortality. The
studies classiﬁed events as non-cardiovascular death when the
event committee classiﬁed the events based on supportive mate-
rial emergency room reports, hospital notes, discharge summaries,
autopsy reports, laboratory tests, ECG, etc. The non-cardiovascular
mortality mainly included cancer, sepsis, trauma, pulmonary dis-
ease, non-cardiac surgery, suicide, and the illness or treatment
complications resulting in death. Vascular deaths, which included
hemorrhage, vascular catastrophe, systemic embolism, pulmonary
embolism, and central nervous system (CNS) events, were also
considered non-cardiovascular deaths. In instances where non-
cardiovascular mortality was not reported, the difference of total
mortalities and cardiovascular mortalities was taken as non-
cardiovascular mortalities.
Cardiovascular mortalities were divided into arrhythmic and
non-arrhythmic cardiac mortalities. The studies in general classi-
ﬁed mortality as cardiac non-arrhythmic, when death occurred
due to congestive heart failure (CHF), shock, or myocardial ische-
mia with evidence of ischemic symptoms, ECG changes, or enzyme
abnormalities. Deaths following collapse, spontaneous and rapid
blood loss, and unexplained death during sleep were classiﬁed as
cardiac arrhythmic mortalities.
2.3. Statistical analysis
An intention-to-treat analysis was used to obtain results for
each trial. Odds ratios (OR) were used as a summary measure of
efﬁcacy for dichotomous data and mean difference (MD) with 95%
conﬁdence interval (CI) was used for continuous variables. Fixed-
effect model was used for the analysis since studies showed low
heterogeneity, which was measured by I2 that describes the per-
centage of total variation across trials due to heterogeneity rather
than chance. I2 can be calculated as I2¼100% (Qvdf)/Q, whereQ is Cochran's heterogeneity statistics and df the degrees of free-
dom. I2 values less than 25% were considered as low heterogeneity,
25–50% as moderate, and greater than 75% as high heterogeneity.
The summary estimators of treatment effect were calculated using
the DerSimonian and Laird ﬁxed-effect method. A p value of 0.05
or less was regarded as signiﬁcant. The number of patients needed
to treat to prevent one end point was calculated using the overall
weight risk difference (NNT¼1/[absolute risk difference]). All
analyses were performed using Review Manager (RevMan) Ver-
sion 5.3 for Windows.3. Results
The initial search yielded 1588 potential literature citations
(Fig. 1). Out of these, we identiﬁed 15 randomized controlled trials
that compared antiarrhythmic medications to AV nodal blocking
agents, ICD or placebo and fulﬁlled our inclusion criteria. The main
reasons for exclusion were that the selected studies did not report
non-cardiac mortality, were not randomized, or were randomized
trials that compared two different AAMs.
3.1. Trial characteristics
The combined search of Medline, Google Scholar, and refer-
ences identiﬁed 1588 articles, 1573 of which were excluded. The
studies that were not randomized or did not report non-cardiac
mortality were excluded (Table 1).
Fifteen trials were selected based on the inclusion and the
exclusion criteria. The trial names, acronyms, details of patient
characteristics and AAMs inclusion are shown in Table 1. Four
trials compared treatment strategies of rhythm-control with AAMs
and rate-control with atrial ﬁbrillation [9–11]. Seven trials eval-
uated the effect of AAMs on mortality in patients who had sur-
vived myocardial infarction [7,8,12–16]. Three of these trials
[13,15,16] enrolled patients with left ventricular dysfunction and
one trial enrolled patients with frequent or repetitive ventricular
premature depolarization [7]. Two trials evaluated the role of
AAMs in patients with ventricular tachycardia [6,17] and one of
the trials included patients with heart failure [17]. ICD where used
in two of the trials as one of the therapies for ventricular tachy-
cardia (VT) [3,4]. One of these two trials included only patients
with non-ischemic cardiomyopathy [6]. The trials included mostly
males between the average mean ages of 60–65 years (Table 1).
The average follow up for all the studies was 2.3 years.
3.2. Trial results
3.2.1. Non-cardiac mortality
Nine out of the 13 trials showed that treatment with AAMs
resulted in non-cardiac mortality; however, only one trial
(AFFIRM) showed a signiﬁcant difference between the treatment
groups. The combined OR of non-cardiac-mortality with AAMs
was associated with an increased risk of non-cardiac deaths by
30% (OR¼1.30, [95% CI: 1.12, 1.50], p¼0.0005, I2¼24%), when
compared to non-arrhythmic therapy (Fig. 2). The analysis was
dominated by the AFFIRM trial [9]. There was no heterogeneity
across the trials (heterogeneity χ2¼17.15, df¼13 (p¼0.19),
I2¼24%). These ﬁndings did not change after excluding the two
trials that included ICD as the placebo arm (OR¼1.30, [1.11, 1.51],
p¼0.001). Three of the trials (AVID, SWORD, DOMOND) included
patients with heart failure or LV dysfunction. When combined,
these trials also showed signiﬁcant increase in non-cardiac mor-
tality (OR¼1.44 [1.00, 2.09] p¼0.050).
Ten of the trials used amiodarone as one of the AAMs. In the
GEMICA trial, the most common cause of death was stroke and
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increase in non-cardiac mortality between the groups. The most
common causes included stroke, cancer, and pulmonary causes.Fig. 1. Search strategy.
Table 1
Baseline characteristics of trials.
Trial name Age (years) Female (%)
AFFIRM [9] AAMa 69.779 39.3
Control 69.879 40.6
AMIOVIRT [6] AAM 60712 26
Control 58711 33
AVID [3] AAM 65.3 19
Control 64.8 22
CAMIAT [7] AAM 64 17.5
Control 64 18
CAST-2 [12] AAM 61.779.9 17.8
Control 62.0710 16.4
CEREMUZYNSKI [8] AAM 59.4712.3 28.9
Control 58.6711.8 31.8
CHF-STAT [17] AAM 6578.5 0.9
Control 66.178.1 1.2
CIDS [4] AAM 63.879.9 16.3
Control 63.379.2 14.6
DIAMOND [16] AAM 68 28
Control 69 25
EMIAT [15] AAM 60.2 15.1
Control 59.6 16.1
GEMICA [14] AAM 60711 19.4
Control 60712 24.9
RACE [10] AAM 6978 35
Control 6979 35
ROY [24] AAM 66711 22
Control 67711 15
STAF [11] AAM 65.379.4 41
Control 66.277.6 32
SWORD [13] AAM 60.4710 14
Control 59.979.8 14
a Anti-arrhythmic medication.The statistically signiﬁcant heterogeneity found among the trials
by I2, is a reﬂection in part of the wide range of sample size of the
individual trials.
3.2.2. All-cause mortality, cardiac mortality, and arrhythmic
mortality
There was also increase in all-cause mortality between patients
taking placebo and AAMs (OR¼1.09 [95% CI: 1.01, 1.18] p¼0.04)
(Fig. 3). There was no difference in cardiac (OR¼1.01 [95% CI: 0.92,
1.11] p¼0.82) or arrhythmic mortality (OR¼1.00 [95% CI: 0.89,
1.13] p¼0.94). Trials were signiﬁcantly heterogeneous for all-cause
mortality, cardiac, and arrhythmic mortality (Figs. 3 and 4).4. Discussion
The present meta-analysis of randomized trials demonstrated
that treatment with AAMs is associated with an increase in non-
cardiac and all-cause mortality as compared to non-arrhythmic
therapy or control group. There was no signiﬁcant reduction in
cardiac or arrhythmic mortality between the two groups. The
ﬁnding was independent of the ICD or AV nodal blocking agents
use in the control group. Amiodarone was the most commonly
used drug in these trials. Current evidences show that amiodarone
is the most effective form of treatment for life threatening
arrhythmias [18,19]. Singh et al. reported that prolonged use of
amiodarone increases the left ventricular ejection fraction possibly
by prolonging repolarization period [20]. Amiodarone primarily
acts by blocking potassium channels, leading to a prolonged
repolarization phase; however, it also has inhibitory effects on
sodium and calcium channels, as well as beta and alpha adrenergic
receptors. Heart Rhythm Society (HRS) has provided class 1C evi-
dence for amiodarone use in atrial ﬁbrillation after considering its
potential toxicities and when other agents have failed or areHTN (%) DM (%) CAD (%) LVEF (%)
50.8 N/A 26.1 54713
51.6 N/A 24.5 54.9713
67 36 11 2378
58 31 4.9 22710
44 76 18 30.7
44 75 18 32.2
41 15 N/A N/A
43 18 N/A N/A
33.6 21.5 N/A 32.378.4
35 21.5 N/A 32.977.9
43.3 19.7 N/A N/A
48.1 18.8 N/A N/A
N/A N/A 72 N/A
N/A N/A 70.7 N/A
N/A N/A 82.2 33714
N/A N/A 82.9 34714
16 13 36 N/A
17 13 37 N/A
N/A 17 26 3078
N/A 17 32 3077
54.8 19 15.7 N/A
51.6 13.4 13.7 N/A
56 11 34 N/A
42 13 38 N/A
49 22 48 2776
46 20 48 2776
63 N/A 34 N/A
62 N/A 53 N/A
37 N/A 34 3176.8
35 N/A 32 3077
Fig. 2. Non-cardiac mortality.
Fig. 3. All-cause mortality.
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can affect the lungs, liver, and thyroid [19]. Multiple larger
population-based trials have shown that AAMs are proarrhythmic
and are capable of increasing cardiac mortality due to their
proarrhythmic effects [4,13,14]. To our knowledge, there are no
reports where primary endpoint was increase in non-cardiac
mortality caused by AAMs (Figs. 5–9).
The ﬁrst study to show an increase in non-cardiac mortality
was the mode-of-death analysis of the AFFIRM study that showed
a signiﬁcant increase in fatal non-cardiovascular events in the
rhythm-control arm [9]. The most commonly used drug in the
AFFIRM trial was amiodarone, prescribed in approximately 60% of
patients. In the study, after adjusting for other signiﬁcant covari-
ates, the risk of non-cardiovascular death was increased 1.5 fold
(p¼0.0007) if the assignment in AFFIRM was to the rhythm-
control arm. It is evident from Fig. 1, that six studies showed an
increased trend in non-cardiac mortality with AAMs; however,none of them were statistically signiﬁcant. Similar ﬁndings were
also observed by Gronefeld et al., showing that signiﬁcant quality
of life at 1 year follow up was better with rate control strategy as
compared to rhythm control strategy [22]. The reasons for increase
in non-cardiac mortality with AAMs are unclear at this time. In our
meta-analysis, the increase in AAMs has been seen in patients
with and without LV dysfunction. Waldo et al. showed increased
mortality with anti-arrhythmic medications in patients with low
ejection fraction [13]; however, subsequent studies did not report
any conﬁrming evidence [13,15,16]. In our meta-analysis AFFIRM is
the only study, which had included patients with normal ejection
fraction, all other studies had patients with low ejection fraction
and seven studies did not specify LV function (Table 2).
Despite its clinical efﬁcacy, amiodarone was found to be asso-
ciated with increased non-cardiac mortality. Its long turn accu-
mulation leads to serious end organ toxicities, mainly manifested
in the lung, liver, and thyroid. A recent retrospective cohort
Fig. 4. Cardiac mortality.
Fig. 5. Arrhythmic mortality (M–H: Mantel–Haenszel, CI: conﬁdence interval, AAM: antiarrhythmic medication).
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atrial ﬁbrillation revealed a higher risk of non-cardiac death in
patients treated with amiodarone compared to other AAMs [23].
Lung toxicity is considered the most serious adverse event, as it
can lead to non-reversible damage and fatal outcomes [24]. Lung
toxicity correlates with the dose and the duration of amiodarone
use, and it can present as early as few days to years after the
treatment is started. Fatal outcomes range from 10% in patients
who develop pneumonitis, up to 50% in patient presenting with
acute respiratory distress syndrome (ARDS) [25]. Amiodarone
exposure was associated with an increased likelihood of interstitial
pneumonitis, which can be explained by its immunologic
mechanism of hypersensitivity [26]. Liver toxicity is a well-known
adverse effect of amiodarone and is related to its cumulative doses.
Symptomatic events are seen in less than 3% of the cases. Most
patients have reversible liver damage; however, death secondary
to cirrhosis and liver failure had been reported in several cases[27]. Several mechanisms had been attributed to thyroid dys-
function after amiodarone use, leading to hypo and hyperthyr-
oidism. However, fatal outcomes had been reported in the litera-
ture in few cases and meta-analysis [28–31]. Optic neuropathy and
corneal deposits had been reported with prolonged use of amio-
darone due to its effect on endothelial and vascular smooth
muscles [32]; few cases of leucocytoclastic vasculitis following
treatment with amiodarone had also been reported explaining its
cutaneous side effects [33].
Amongst other anti-arrhythmic medications, disopyramide
(class 1A AAM) has anticholinergic side effects such as dry mouth,
urinary hesitancy, constipation and exacerbation of conditions like
glaucoma and myasthenia gravis. Disopyramide acts by targeting
the fast sodium channels in the cardiac tissue. However, it also
blocks potassium channels in pancreatic cells, which increases
insulin secretion, leading to episodes of hypoglycemia, resulting in
coma and neurological damage. This side effect is seen at normal
Fig. 6. Total mortality amiodarone.
Fig. 7. Amiodarone cardiac mortality.
Fig. 8. Amiodarone non-cardiovascular mortality.
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taking potassium (ATP) channel inhibitor such as glimepiride [35].
Procainamide was widely used in the past; however, its use has
been limited as its chronic administration leads to frequent side
effects manifested mainly by lupus like syndrome in around 30% ofpatients [36]. On the other hand, bone marrow toxicity is a serious
but less frequent side effect, manifested in less than 0.22% of the
patients. It should be considered in any patient who develops
pancytopenia once procainamide treatment is stopped [37].
Mexelitine is a well-tolerated class 1B antiarrhythmic drug. Its side
Fig. 9. Amiodarone arrhythmic mortality. (M–H: Mantel–Haenszel, CI: conﬁdence interval, AAM: antiarrhythmic medication).
Table 2
Trials with amiodarone as the main anti-arrhythmic medication.
Trial name Total Pt. n (%) who used amiodarone
AFFIRM [9] 1277 (62.8)
AMIOVIRT [6] 52 (100)
AVID [3] 475 (95.8)
CAMIAT [7] 606 (100)
CEREMUZYNSKI [8] 305 (100)
CHF-STAT [17] 336 (100)
CIDS [4] 331 (100)
EMIAT [15] 743 (100)
GEMICA [14] 542 (100)
ROY [24] 559 (82)
B. Pandya et al. / Journal of Arrhythmia 32 (2016) 204–211210effects are limited to gastrointestinal (GI) and neurological mani-
festation such as dizziness and numbness [38]. However more
serious effects like thrombocytopenia are rare, and are based on
case reports [39]. Propafenone is a Class 1C antiarrhythmic drug. It
has been reported to be associated with suppressive sympathetic
effects such as dizziness, nausea, visual disturbances [40]. A
negative inotropic effect of propafenone signiﬁcantly increases
pulmonary capillary wedge pressure, systemic and pulmonary
vascular resistance, and cardiac output especially in patients with
low ejection fraction, leading to increase in non-cardiac mortality
and morbidity [41]. Although GI side effects such as nausea and
metallic taste are frequent and mild, propafenone has been
implicated in acute cholestatic hepatitis as described in a case
report [42].
In 10 out of the 15 trials included in the analysis, amiodarone
was the major antiarrhythmic prescribed. Moreover, in 9 out of the
15 trials, there was an increase in non-cardiac mortality and in
8 out of 15 trials, there was an increase in all-cause mortality with
AAMs while cardiac or arrhythmic mortalities remained the same.
The increase in non-cardiac mortality was mainly attributed to
increased incidence of all-cause mortality
4.1. Strengths and limitations
Our meta-analysis had several strengths that are as follows: a
comprehensive search for relevant studies was conducted, all the
included trials were randomized controlled, the eligibility criteria
were applied systematically and explicitly, study quality was
considered carefully, and a rigorous analytical approach was used.
However, there were some limitations of the analysis. First, the
sample sizes were different in various studies, affecting their sta-
tistical power in the analyses. Second, the studies that wereincluded showed signiﬁcant heterogeneity as evidenced by high I2
value; however, that might be expected as we had included stu-
dies with different protocols. Thirdly, the amiodarone dose was
not similar in all the studies.5. Conclusion
Non-cardiac and all-cause mortality rates are reportedly higher
with AAMs compared to non-arrhythmic therapy. This effect of
AAMs especially amiodarone, on non-cardiac mortality requires
further evaluation.Conﬂict of interest
All authors declare no conﬂict of interest related to this study.References
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